Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,